A2022 PCG Acquisitions
Total Consideration
$406.0M
2 years of history · ending 2024-12-28 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 6.60% | 22.40% | 14.20% | -0.70% | 3.10% | 2.40% |
| Foreign Rate Differential | 0.70% | -12.10% | -6.10% | -0.30% | -0.30% | 0.70% |
| Other Adjustments | 2.80% | -9.00% | -2.70% | -9.50% | -0.40% | -1.70% |
| SBC (Nondeductible) | 0.00% | 3.90% | 1.70% | 1.80% | -0.20% | -2.00% |
| Nondeductible Expenses | 6.70% | 14.10% | 30.20% | 0.00% | 0.00% | 0.00% |
| Valuation Allowance Change | 0.00% | 48.20% | 12.80% | 6.10% | -2.00% | -16.50% |
| Tax Settlements (Foreign) | — | 0.00% | 0.00% | 7.60% | -0.30% | 0.30% |
| Effective Tax Rate | 38.40% | 1.59% | 72.70% | 36.80% | 12.10% | 7.90% |
Cash vs Accrual
| Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $4.8M | $11.4M | $25.4M | $25.2M | −$102.7M | −$25.1M |
| Income Taxes Paid (Cash) | — | — | — | — | — | — |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$406.0M
Total Consideration
$171.0M
Total Consideration
$38.0M
Purchase-Price Allocation
Intangibles
$49.0M
Total Consideration
$15.3M
Purchase-Price Allocation
Goodwill
$4.1M
Assets Acquired
$12.4M
Liabilities Assumed
$1.2M
Total Consideration
$8.6M
Purchase-Price Allocation
Goodwill
$4.7M
Assets Acquired
$7.5M
Liabilities Assumed
$3.7M
Total Consideration
$5.6M
Purchase-Price Allocation
Goodwill
$4.9M
Assets Acquired
$702.0K
Pro-Forma Combined Entity
Revenue
$2.17B
Net Income
+$66.2M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).